These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27713618)

  • 21. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators.
    Taillefer R; Edell S; Innes G; Lister-James J
    J Nucl Med; 2000 Jul; 41(7):1214-23. PubMed ID: 10914912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets.
    Schwarz M; Meade G; Stoll P; Ylanne J; Bassler N; Chen YC; Hagemeyer CE; Ahrens I; Moran N; Kenny D; Fitzgerald D; Bode C; Peter K
    Circ Res; 2006 Jul; 99(1):25-33. PubMed ID: 16778135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP; Peyrou V; Savi P; Bernat A; Herbert JM
    Thromb Haemost; 1998 Feb; 79(2):383-8. PubMed ID: 9493595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.
    Barlage S; Wimmer A; Pfeiffer A; Rothe G; Schmitz G
    Platelets; 2002 May; 13(3):133-40. PubMed ID: 12180495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
    Rao AK; Sun L; Hiramatsu Y; Gorman JH; Edmunds LH
    Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: a preliminary report.
    Klem JA; Schaffer JV; Crane PD; Barrett JA; Henry GA; Canestri L; Ezekowitz MD
    J Nucl Cardiol; 2000; 7(4):359-64. PubMed ID: 10958278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of streptokinase-induced, antibody-mediated platelet aggregation with tirofiban after exposure to streptokinase or streptococcal infection.
    Courval M; Palisaitis DA; Diodati JG; Lesperance B; Pharand C
    Pharmacotherapy; 2004 May; 24(5):558-63. PubMed ID: 15162889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.
    Derhaschnig U; Pachinger C; Jilma B
    Am Heart J; 2004 Apr; 147(4):E17. PubMed ID: 15077100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest.
    Straub A; Azevedo R; Beierlein W; Wendel HP; Dietz K; Ziemer G
    Thromb Haemost; 2005 Jul; 94(1):115-22. PubMed ID: 16113794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of platelets aggregation in the process of ductus arteriosus closure of newborn pups].
    Ren Y; Gao X; Zhao D; Wang L; Huang D; Su M
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Nov; 34(11):1194-1199. PubMed ID: 36567565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
    Kondo K; Umemura K
    Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
    Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
    J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tirofiban blocks platelet adhesion to fibrin with minimal perturbation of GpIIb/IIIa structure.
    Hantgan RR; Stahle MC; Jerome WG; Nagaswami C; Weisel JW
    Thromb Haemost; 2002 May; 87(5):910-7. PubMed ID: 12038797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of platelets by the GPIIb/IIIa receptor antagonist Tirofiban reduces leukocyte-endothelial cell interaction in murine antigen-induced arthritis.
    Schmitt-Sody M; Metz P; Gottschalk O; Zysk S; Birkenmaier C; Goebl M; von Schulze Pellengahr C; Veihelmann A; Jansson V
    Inflamm Res; 2007 Oct; 56(10):414-20. PubMed ID: 18026698
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.